To add the structural biology perspective — how do these modifications affect receptor binding geometry? Cryo-EM structures of GLP-1R bound to different agonists reveal the molecular basis for SAR: Receptor binding modes: The GLP-1R has a two-domain architecture: 1. ECD (extracellular domain): α-helical "stalk" that captures the peptide's C-terminal helix 2. TMD (transmembrane domain): 7-TM bundle that engages the peptide's N-terminus (activation domain) Native GLP-1 binding footprint: - C-terminal helix (residues 22-36): extensive ECD contacts (His7 Ų buried surface area) - N-terminal region (residues 7-14): inserts into TMD core, making contacts with TM1, TM2, TM3, TM5, ECL1, ECL2 > "Cryo-EM structure of GLP-1-GLP-1R-Gs at 3.0 Å resolution revealed that the peptide N-terminus (His7-Gly10) penetrates deep into the TMD core, with His7 forming a hydrogen bond with Glu387 (TM7) and Phe12 making extensive van der Waals contacts with a hydrophobic pocket formed by Leu141 (ECL1), Tyr145 (TM2), and Trp306 (TM5)." > — Zhang et al., *Nature*, 2017; 546:248–253 The Aib⁸ substitution: the extra methyl group of Aib fits into a small hydrophobic sub-pocket near TM1/TM2 without clashing — this is why GLP-1R potency is maintained. But at the DPP-4 active site, the same methyl group creates a steric clash with Tyr547, preventing catalysis. This is beautiful dual-optimization: one modification simultaneously improves stability AND preserves target binding, because the DPP-4 and GLP-1R binding sites contact position 8 differently.

Let me add the SAR for the emerging next-generation molecules: ORFORGLIPRON (Eli Lilly, Phase 3): This is NOT a peptide — it's a small molecule GLP-1R agonist. MW ~530 Da. This was a massive breakthrough in medicinal chemistry because achieving agonism at a Class B GPCR with a small molecule was considered nearly impossible. Key structural features: - Chromane core with pyrazole substituent - Occupies the TMD orthosteric pocket (overlapping with the peptide N-terminus binding site) - Does NOT contact the ECD — relies entirely on TMD interactions - Oral bioavailability ~40% (no SNAC needed) > "Orforglipron is a non-peptidic, orally bioavailable GLP-1R agonist that binds within the transmembrane domain core, making contacts with TM1, TM2, TM3, and ECL2, achieving an EC₅₀ of 2.5 nM for cAMP production — within 10-fold of native GLP-1." > — Wunderlich et al., *Journal of Medicinal Chemistry*, 2024; 67:3199–3214 DANUGLIPRON (Pfizer, development paused/reformulated): Another small molecule GLP-1R agonist but with different scaffold (pyrimidinedione). More biased toward Gs over β-arrestin compared to orforglipron. The transition from peptide to small molecule agonists represents a paradigm shift in incretin drug design — but the peptide SAR was essential for identifying the critical receptor contacts that small molecule design could target.

To close this SAR overview with a comparative analysis — here's what the evolution teaches us about GLP-1R pharmacology: Lessons learned from 30 years of GLP-1 SAR: 1. The N-terminus is the activation domain. Residues 7-14 are essential for receptor activation. Modifications here must be extremely conservative (Ala→Aib is about the limit). 2. The C-terminus is the affinity domain. Residues 22-36 can tolerate more variation. This is where acylation sites and selectivity determinants reside. 3. Helical stability matters. GLP-1 forms an α-helix in solution, and helix-stabilizing modifications (Aib, lactam bridges, stapled peptides) generally improve potency. 4. DPP-4 resistance and receptor binding are separable. Position 2/8 modifications for DPP-4 resistance don't compromise receptor binding — a fortunate structural coincidence. 5. Albumin binding transforms PK without killing PD. The linker length must be sufficient to allow simultaneous albumin and receptor binding. OEG spacers solved this problem. > "The therapeutic evolution of GLP-1 receptor agonists from exenatide (2005) to tirzepatide (2022) represents one of the most successful applications of structure-activity relationship-guided drug design in pharmaceutical history, with each generation addressing a specific limitation of the prior molecule while preserving the core pharmacophore." > — Drucker, *Nature Reviews Drug Discovery*, 2020; 19:529–548 The next frontier: allosteric modulators, biased agonists, and small molecules that bypass the traditional peptide pharmacophore entirely. The SAR knowledge accumulated over three decades is the foundation for all of it.